what is semaglutide approved for FDA Approval vs Compounded Alternatives US FDA approves weight loss

Some patients notice facial changes within the first 3 to 6 months, particularly if weight loss is rapid

While most nausea from GLP-1 therapies is self-limited, serious adverse events such as pancreatitis, severe dehydration, or gallbladder disease require immediate attention and possibly discontinuation of the medication

Case Report A 68-year-old male known for hypertension and type II diabetes was admitted to the critical care unit of a community hospital following an overdose of amlodipine and metformin

Search strategy and study selection We conducted a comprehensive systematic search across five electronic databases: PubMed, Embase, Web of Science, Scopus, and the Cochrane Library, as well as the Google Scholar search engine, from inception to September 30, 2025, to identify studies investigating the association between GLP-1 receptor agonists and AUD outcomes